The renal anemia market was valued at USD 5.28 Billion in 2025, driven by the increasing prevalence of chronic kidney disease across the 8 major markets. The market is expected to grow at a CAGR of 7.50% during the forecast period of 2026-2035, with the values likely to reach USD 10.88 Billion by 2035.
Base Year
Historical Period
Forecast Period
The rising prevalence of chronic kidney disease along with the increasing risk factors such as diabetes, hypertension, and an aging population, are primary drivers of the market.
The robust regulatory support from health authorities like the FDA and ongoing research and development efforts to improve therapeutic options for renal anemia is likely to elevate the market value.
The surge in new drug approvals by regulatory bodies such as the United States FDA is a major market trend.
Compound Annual Growth Rate
7.5%
Value in USD Billion
2026-2035
*this image is indicative*
Renal anemia is a common complication of chronic kidney disease and is associated with significant morbidity and mortality. It occurs in over 90% of patients receiving renal replacement therapy. Renal anemia is primarily caused by a reduction in erythropoietin production in the kidneys. The market for renal anemia is driven by the increasing prevalence of chronic kidney disease and the growing aging population. The rising adoption of novel therapies such as hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) and the shift towards combination therapies are major trends poised to support market growth. Moreover, innovations in iron supplementation methods, the expansion of healthcare infrastructure, and rising diagnosis rates are some of the factors projected to shape the market landscape.
Increasing Prevalence of Chronic Kidney Disease to Drive Market Growth
Recent data suggests that the global prevalence of chronic kidney disease (CKD) is around 13.4% (11.7-15.1% ). Anemia is a common complication of chronic kidney disease and is linked with CKD progression, cognitive impairment, increased risk of hospitalization, and reduced quality of life, among others. The prevalence of anemia in chronic kidney disease varies across regions, with around 500,000 adult patients on dialysis affected by anemia due to chronic kidney disease in the United States. Thus, the rising burden of chronic kidney disease is one of the primary drivers of the market.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Renal Anemia Market Report and Forecast 2026-2035 offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Breakup by Treatment Type
Market Breakup by Route of Administration
Market Breakup by End-user
Market Breakup by Region
Market Segmentation Based on Treatment Type is Anticipated to Witness Substantial Growth
The market segmentation based on treatment type includes iron supplements, erythropoiesis-stimulating agents (ESAs), vitamin B12 supplements, transfusion therapy, bone marrow transplant, and others. Erythropoiesis-stimulating agents (ESAs) are commonly used in the treatment of renal anemia. They are known to stimulate the bone marrow to produce more red blood cells and are widely used in both dialysis and non-dialysis patients. ESAs are typically administered via injection and are reported to reduce the need for blood transfusions in chronic kidney disease patients.
The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States is a leading market for renal anemia owing to the high prevalence of chronic kidney and a growing aging population. The easy access to innovative treatments like erythropoiesis-stimulating agents (ESAs) and hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in the country further supports the market growth. Moreover, the robust regulatory support from health authorities like the FDA and ongoing research and development efforts to improve therapeutic options for renal anemia is anticipated to aid the market expansion in the region in the forecast period.
The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
AstraZeneca, a major pharmaceutical and biotechnology company, is headquartered in Cambridge, United Kingdom. The company’s first-in-class orally administered small molecule, Roxadusta t is indicated for the treatment of anemia in chronic kidney disease patients on dialysis. Roxadustat has received regulatory approval in a number of countries including China and Japan.
This British multinational pharmaceutical and biotechnology company is one of the leading players in the market, known for its solutions in renal anemia management. In February 2023 , GSK's Jesduvroq (daprodustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), received approval from the US Food and Drug Administration (FDA) for the treatment of anemia of chronic kidney disease in adult patients on dialysis.
F. Hoffmann-La Roche Ltd (Roche), a Swiss multinational holding healthcare company, has a prominent presence in the market and is known for its biologics and advanced pharmaceuticals that treat a variety of chronic conditions, including CKD-related anemia. One of its key products is Recormon® pre-filled syringes which are used for the treatment of renal anemia.
Japanese multinational pharmaceutical company Astellas Pharma plays a significant role in the market and is focused on offering novel therapeutic options for anemia management in chronic kidney disease patients. Its drug Evrenzo® (generic name: roxadustat) is approved for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis in Japan.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Amgen Inc., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Sanofi, AbbVie Inc., and Pfizer.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Treatment Type |
|
| Breakup by Route of Administration |
|
| Breakup by End-user |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share